David Ricks

David Ricks, CEO of Eli Lilly, leads the pharmaceutical giant in innovative ventures, particularly with groundbreaking weight-loss drugs showing promise for various health issues. He discusses the surprising benefits of diabetes medications in combating obesity and their implications for chronic diseases. Ricks reveals how AI is revolutionizing drug development, allowing companies to cut timelines dramatically. He emphasizes the importance of curiosity-driven leadership and open communication in fostering a collaborative workplace culture.

David Ricks, Chair and CEO of Eli Lilly, discusses the groundbreaking advances in weight-reducing drugs that extend their benefits beyond initial intentions, like treating addiction and Alzheimer's. He highlights how Eli Lilly has halved drug development timelines through innovative approaches and AI. Ricks also navigates the challenges of drug pricing ethics in different markets, emphasizing the balance between patient access and business sustainability. This conversation reveals the exciting future of medicine and its transformative potential.

In this engaging discussion, David Ricks, CEO of Eli Lilly and a pioneer in diabetes and weight-loss medications, delves into the transformative impact of GLP-1 drugs like Ozempic. He highlights the potential for 9% of Americans using these medications by 2030 and discusses the company's skyrocketing revenue from innovative treatments. Ricks also explores how these drugs could revolutionize addiction treatment and disrupt various industries, reshaping health and consumer behavior for years to come.

David Ricks, Global CEO of Eli Lilly, shares insights on tackling chronic diseases in India with the launch of Manjaro for obesity and diabetes. He discusses the delicate balance of pricing strategies that ensure accessibility while remaining profitable. Ricks also emphasizes the power of strategic partnerships in enhancing healthcare, from local businesses to tech innovations. He sheds light on the transformative role of biotechnology in health solutions and the challenges posed by political and regulatory landscapes within the pharmaceutical industry.

David Ricks, the Chairman & CEO of Eli Lilly, shares insights on the company's strategic decision to expand US manufacturing, emphasizing its impact on the pharmaceutical landscape. Carl Eschenbach, CEO of Workday, highlights a strong quarterly performance while discussing the surging demand for AI solutions in the workforce. The conversation also touches on significant market shifts, including Tesla's declining valuation and potential tariff impacts on copper, setting a dynamic backdrop for economic growth and corporate strategies.